Efficacy and safety of first‐line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study

2020 ◽  
Vol 27 (12) ◽  
pp. 1095-1100 ◽  
Author(s):  
Toshikazu Tanaka ◽  
Shingo Hatakeyama ◽  
Kazuyuki Numakura ◽  
Koichi Kido ◽  
Daisuke Noro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retrospective Study ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Efficacy And Safety ◽  
First Line

Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study

2019 ◽  
Vol 17 (5) ◽  
pp. e1080-e1089 ◽  
Author(s):  
Sakae Konishi ◽  
Shingo Hatakeyama ◽  
Kazuyuki Numakura ◽  
Shintaro Narita ◽  
Takamitsu Inoue ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retrospective Study ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Model ◽  
First Line

scholarly journals Efficacy and Safety of Axitinib as First-Line Therapy in Japanese Patients with Metastatic Renal Cell Carcinoma

2015 ◽  
Vol 06 (08) ◽  
pp. 670-678 ◽  
Author(s):  
Takeshi Namekawa ◽  
Satoshi Fukasawa ◽  
Atsushi Komaru ◽  
Masayuki Kobayashi ◽  
Takayuki Ohzeki ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma

2018 ◽  
Vol 14 (18) ◽  
pp. 1835-1845 ◽  
Author(s):  
Shu-Kui Qin ◽  
Jie Jin ◽  
Jun Guo ◽  
Jin-Wan Wang ◽  
Fang-Jian Zhou ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Chinese Patients ◽  
Efficacy And Safety ◽  
First Line

scholarly journals Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study

2015 ◽  
Vol 6 (4) ◽  
pp. 23-27
Author(s):  
Hend Ahmed El-Hadaad ◽  
Hanan Ahmed Wahba ◽  
Hayam Fathy Abd-El Hay Ghazy
Keyword(s):  
Renal Cell Carcinoma ◽  
Retrospective Study ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Line Treatment ◽  
First Line ◽  
Number Of Patients ◽  
First Line Treatment

Abstract Background: Targeted agents were introduced over past years because of better understanding of oncogenetic mechanisms in metastatic renal cell carcinoma (mRCC). These agents include tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, pazopanib and axitinib. Methods: Review of recorded data from patients’ files with mRCC were analysed during the period from August 2008 to December 2014. Those patients were treated by sunitinib as first-line therapy. The data included patients characteristics such as age, sex, ECOG performance status (ECOG PS), number and sites of metastasis and pathological type. Also, we reviewed response to sunitinib therapy, its adverse events and progression-free survival (PFS). Results: This study included 26 patients; median age was 56 years with male predominance (76.9%) and 61.5% of patients were of ECOG PS0. Lymph nodes were the most common site of metastasis (38.5%) and 46.2% presented with ≥3 sites of disease. Clear cell pathology was reported in 96.2%. No grade IV adverse events to sunitinib reactions were observed. Thrombocytopenia was the most predominant haematological reaction (46%) followed by neutropenia (38.6%), whilst fatigue was the most reported non-haematological one (50%) followed by diarrhoea (42.3%). Partial response (PR) was found in 30.8% and stable disease (SD) in 46.2%. One-year PFS was 57.7% with median PFS time of 12 months. Conclusion: This study proved effectiveness and safety of sunitinib as first-line treatment for mRCC. However, this is a retrospective study and relatively small numbers of patients were included, so prospective studies with larger number of patients are needed for further evaluation.

Sign in / Sign up

Export Citation Format

Share Document